Vitamin D as an Early Predictor of Multiple Sclerosis Ac

JAMA Neurology

71, 306

DOI: 10.1001/jamaneurol.2013.5993

Citation Report

#	Article	IF	Citations
1	Mitochondrial DNA Mutation in Microglia Can Be Treated by SCNT Cloning and Not by Reprogramming of Olfactory Ensheathing Cells in the Multiple Sclerosis Treatment. Journal of Multiple Sclerosis, 2014, 02, .	0.1	0
2	Vitamin Dâ€"Binding Protein Levels Do Not Influence The Effect of Vitamin D Repletion on Serum PTH and Calcium: Data From a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2494-2499.	1.8	36
3	Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. Therapeutic Advances in Neurological Disorders, 2014, 7, 279-288.	1.5	10
8	Not too late to take vitamin <scp>D</scp> supplements. Annals of Neurology, 2014, 76, 321-322.	2.8	7
9	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of Neurology, 2014, 75, 739-758.	2.8	100
10	Vitamin D status and the risk of multiple sclerosis: A systematic review and meta-analysis. Neuroscience Letters, 2014, 570, 108-113.	1.0	98
11	Low Vitamin D levels predict clinical features of schizophrenia. Schizophrenia Research, 2014, 159, 543-545.	1.1	53
12	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemporary Clinical Trials, 2014, 39, 288-293.	0.8	64
13	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology, 2014, 1, 605-617.	1.7	44
14	How Type I Interferons Work in Multiple Sclerosis and Other Diseases: Some Unexpected Mechanisms. Journal of Interferon and Cytokine Research, 2014, 34, 589-599.	0.5	69
15	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	1.2	14
16	Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood. Psychoneuroendocrinology, 2014, 50, 210-219.	1.3	85
17	Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future. Revue Neurologique, 2014, 170, 602-607.	0.6	1
18	Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions. CNS Drugs, 2014, 28, 731-742.	2.7	34
19	Environmental Factors and Multiple Sclerosis Severity: A Descriptive Study. International Journal of Environmental Research and Public Health, 2014, 11, 6417-6432.	1.2	41
20	Modifiable environmental factors in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2014, 72, 889-894.	0.3	20
21	The effect of multiple sclerosis on oral health. Dental Nursing, 2014, 10, 212-216.	0.0	0
22	Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?. NPJ Schizophrenia, 2015, 1, 15036.	2.0	0

#	Article	IF	Citations
23	Vitamin D in Multiple Sclerosis and Central Nervous System Demyelinating Diseaseâ€"A Review. Journal of Neuro-Ophthalmology, 2015, 35, 194-200.	0.4	18
24	Vitamin D is Not a Protective Factor in <scp>ALS</scp>. CNS Neuroscience and Therapeutics, 2015, 21, 651-656.	1.9	32
25	UV Irradiation of Skin Regulates a Murine Model of Multiple Sclerosis. Journal of Multiple Sclerosis, 2015, 02, .	0.1	0
26	CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes. PLoS ONE, 2015, 10, e0122045.	1.1	13
27	The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait. PLoS ONE, 2015, 10, e0142265.	1.1	36
28	Update in vitamin D and multiple sclerosis. Journal of King Abdulaziz University, Islamic Economics, 2015, 20, 329-335.	0.5	58
29	Factors Affecting 25-Hydroxyvitamin D Concentration in Response to Vitamin D Supplementation. Nutrients, 2015, 7, 5111-5142.	1.7	152
31	Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 543-546.	0.9	50
32	Vitamin D levels in multiple sclerosis patients: Association with TGF-Î²2, TGF-Î²RI, and TGF-Î²RII expression. Life Sciences, 2015, 134, 63-67.	2.0	21
33	Advances in the immunopathogenesis of multiple sclerosis. Current Opinion in Neurology, 2015, 28, 206-219.	1.8	134
34	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	0.9	95
36	Vitamin D levels at birth and risk of type 1 diabetes in childhood: a caseâ€"control study. Acta Diabetologica, 2015, 52, 1077-1081.	1.2	31
37	Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. Neuroepidemiology, 2015, 44, 199-214.	1.1	124
38	Effect of vitamin D on MS activity by disease-modifying therapy class. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e167.	3.1	47
39	A New Genetic Study Associates Low Vitamin D and Risk for Multiple Sclerosis. Neurology Today: an Official Publication of the American Academy of Neurology, 2015, 15, 1.	0.0	0
40	Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. Journal of Neuroimmunology, 2015, 280, 12-15.	1.1	42
41	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
42	Imaging Phenotypes in Multiple Sclerosis. Neuroimaging Clinics of North America, 2015, 25, 83-96.	0.5	8

#	Article	IF	Citations
43	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurology, The, 2015, 14, 208-223.	4.9	188
44	Nutrition Facts in Multiple Sclerosis. ASN Neuro, 2015, 7, 175909141456818.	1.5	169
45	We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: No. Multiple Sclerosis Journal, 2015, 21, 37-38.	1.4	2
46	Vitamin D Actions on CD4+ T Cells in Autoimmune Disease. Frontiers in Immunology, 2015, 6, 100.	2.2	93
47	Peripheral blood biomarkers in multiple sclerosis. Autoimmunity Reviews, 2015, 14, 1097-1110.	2.5	55
49	Increased Circulating Levels of Vitamin D Binding Protein in MS Patients. Toxins, 2015, 7, 129-137.	1.5	34
50	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 967-968.	1.4	11
51	The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway â^' Commentary. Multiple Sclerosis Journal, 2015, 21, 856-857.	1.4	0
52	Genetic polymorphisms related to vitamin D and the therapeutic potential of vitamin D in multiple sclerosis. Canadian Journal of Physiology and Pharmacology, 2015, 93, 319-325.	0.7	7
53	25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis. Journal of Neurology, 2015, 262, 1646-1654.	1.8	10
54	The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Progress in Neurobiology, 2015, 127-128, 1-22.	2.8	116
55	Associations Between Serum 25â€Hydroxyvitamin D and Periodontal Pocketing and Gingival Bleeding: Results of a Study in a Nonâ€Smoking Population in Finland. Journal of Periodontology, 2015, 86, 755-765.	1.7	27
56	Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease. Endocrine, 2015, 50, 231-238.	1.1	50
57	Update on clinically isolated syndrome. Presse Medicale, 2015, 44, e121-e136.	0.8	11
58	Environmental factors in multiple sclerosis. Presse Medicale, 2015, 44, e113-e120.	0.8	20
59	Risk factors for multiple sclerosis and associations with anti-EBV antibody titers. Clinical Immunology, 2015, 158, 59-66.	1.4	23
60	Complementary and alternative medicine in multiple sclerosis. Neurology: Clinical Practice, 2015, 5, 74-79.	0.8	4
61	Vitamin D status and effect of interferon-Î²1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2015, 280, 21-28.	1.1	19

#	Article	IF	Citations
62	Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegenerative Disease Management, 2015, 5, 413-424.	1.2	71
63	Vitamin D and multiple sclerosis-from epidemiology to prevention. Acta Neurologica Scandinavica, 2015, 132, 56-61.	1.0	30
64	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	4.5	130
65	Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology, 2015, 262, 2713-2721.	1.8	36
66	Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain, 2015, 138, 3581-3597.	3.7	159
67	Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?. Journal of the Neurological Sciences, 2015, 358, 417-418.	0.3	7
68	Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell, 2015, 162, 1338-1352.	13.5	249
70	â€œDisease modifying nutricalsâ€•for multiple sclerosis. , 2015, 148, 85-113.		42
71	The Immunobiology of Multiple Sclerosis. , 2016, , 180-191.		2
72	Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility. PLoS ONE, 2016, 11, e0149200.	1.1	17
73	Farming, Foreign Holidays, and Vitamin D in Orkney. PLoS ONE, 2016, 11, e0155633.	1.1	5
74	Symptomatic and Complementary Treatments. , 2016, , 347-364.		0
75	Vitamin D, <scp>HLA</scp>â€<scp>DRB</scp>1 and Epsteinâ€“Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology, 2016, 23, 1064-1070.	1.7	29
76	Vitamin <scp>D</scp> in clinically isolated syndrome: evidence for possible neuroprotection. European Journal of Neurology, 2016, 23, 327-332.	1.7	34
77	Computational modeling of brain pathologies: the case of multiple sclerosis. Briefings in Bioinformatics, 2018, 19, bbw123.	3.2	4
78	Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. European Journal of Clinical Nutrition, 2016, 70, 995-999.	1.3	25
79	Association between seasonal factors and multiple sclerosis. European Journal of Epidemiology, 2016, 31, 1081-1089.	2.5	26
80	Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. Expert Review of Clinical Immunology, 2016, 12, 1069-1089.	1.3	21

#	Article	IF	Citations
81	Epidemiology of Multiple Sclerosis: From Risk Factors to Preventionâ€"An Update. Seminars in Neurology, 2016, 36, 103-114.	0.5	209
82	Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future. Seminars in Neurology, 2016, 36, 128-139.	0.5	0
83	Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurology: Genetics, 2016, 2, e97.	0.9	166
84	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. Multiple Sclerosis Journal, 2016, 22, 18-33.	1.4	20
85	Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cellular and Molecular Life Sciences, 2016, 73, 4611-4622.	2.4	82
86	The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China. Journal of Neuroimmunology, 2016, 297, 127-131.	1.1	18
87	Illuminating vitamin D effects on B cells â€“ the multiple sclerosis perspective. Immunology, 2016, 147, 275-284.	2.0	50
88	International Pediatric MS Study Group Global Members Symposium report. Neurology, 2016, 87, S110-6.	1.5	19
89	Vitamin D receptor polymorphisms and Parkinsonâ€™s disease in a Korean population: Revisited. Neuroscience Letters, 2016, 628, 230-235.	1.0	14
90	Antiâ€inflammatory effects of melatonin in multiple sclerosis. BioEssays, 2016, 38, 1016-1026.	1.2	36
91	Longâ€term evolution of multiple sclerosis disability in the treatment era. Annals of Neurology, 2016, 80, 499-510.	2.8	331
92	Network of nuclear receptor ligands in multiple sclerosis: Common pathways and interactions of sex-steroids, corticosteroids and vitamin D3-derived molecules. Autoimmunity Reviews, 2016, 15, 900-910.	2.5	17
94	A population-based epidemiologic study of adult-onset narcolepsy incidence and associated risk factors, 2004â€"2013. Journal of the Neurological Sciences, 2016, 370, 29-34.	0.3	9
95	Estimated economic benefit of increasing 25-hydroxyvitamin D concentrations of Canadians to or above 100Ânmol/L. Dermato-Endocrinology, 2016, 8, e1248324.	1.9	21
96	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 169-173.	0.9	68
97	Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS. Neurology: Clinical Practice, 2016, 6, 329-338.	0.8	29
98	Multiple sclerosis is prominent in the Gulf states: Review. Pathogenesis, 2016, 3, 19-38.	0.8	24
99	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954.	4.5	17

#	Article	IF	Citations
100	Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?. Expert Review of Neurotherapeutics, 2016, 16, 233-235.	1.4	6
101	Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. Experimental Biology and Medicine, 2016, 241, 620-635.	1.1	66
102	Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis â€" A pilot study. Journal of Neuroimmunology, 2016, 293, 59-64.	1.1	16
103	Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?. Trends in Neurosciences, 2016, 39, 325-339.	4.2	83
104	Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis. Journal of Neuroimmunology, 2016, 294, 18-26.	1.1	24
105	Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil. Journal of the Neurological Sciences, 2016, 363, 236-239.	0.3	8
106	Vitamin D deficiency and its role in neurological conditions: A review. Revue Neurologique, 2016, 172, 109-122.	0.6	80
107	Environmental effects of ozone depletion and its interactions with climate change: progress report, 2015. Photochemical and Photobiological Sciences, 2016, 15, 141-174.	1.6	48
108	A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 254-257.	1.2	32
109	Vitamin D and axonal injury in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1027-1031.	1.4	39
110	The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli. Multiple Sclerosis Journal, 2016, 22, 999-1006.	1.4	19
111	Promoting sympathovagal balance in multiple sclerosis; pharmacological, non-pharmacological, and surgical strategies. Autoimmunity Reviews, 2016, 15, 113-123.	2.5	16
112	Modulatory effects of 1,25-dihydroxyvitamin D3 on eye disorders: A critical review. Critical Reviews in Food Science and Nutrition, 2017, 57, 559-565.	5.4	35
113	Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D. Journal of Pharmacy Practice, 2017, 30, 172-179.	0.5	3
114	Papel de la microbiota intestinal en el desarrollo de la esclerosis mÃºltiple. NeurologÃa, 2017, 32, 175-184.	0.3	27
115	Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland. Acta Neurologica Scandinavica, 2017, 135, 516-521.	1.0	10
116	Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2017, 958, 91-127.	0.8	88
117	Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients. Journal of the Neurological Sciences, 2017, 375, 160-164.	0.3	26

#	Article	IF	Citations
118	A systematic review of modifiable risk factors in the progression of multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 525-533.	1.4	57
119	Association of vitamin D status and clinical and radiological outcomes in a treated MS population in Poland. Brain and Behavior, 2017, 7, e00609.	1.0	12
120	Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement. Journal of Rheumatology, 2017, 44, 473-481.	1.0	18
121	Radiologically isolated syndrome and clinically isolated syndrome. Clinical and Experimental Neuroimmunology, 2017, 8, 24-32.	0.5	6
122	Multiple Sclerosis: An Overview. , 2017, , 1-16.		2
123	Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. The Cochrane Library, 2017, 4, CD012200.	1.5	20
124	Multiple Sclerosis: Clinical Features, Immunopathogenesis, and Treatment. , 2017, , 25-75.		1
125	Vitamin D and plasma cell dyscrasias: reviewing the significance. Annals of Hematology, 2017, 96, 1271-1277.	0.8	7
126	Seasonality and autoimmune diseases: The contribution of the four seasons to the mosaic of autoimmunity. Journal of Autoimmunity, 2017, 82, 13-30.	3.0	134
127	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. Drug Safety, 2017, 40, 823-834.	1.4	6
128	Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis. Clinical Immunology, 2017, 181, 9-15.	1.4	13
129	Cigarette Smoking, Alcohol Consumption and Overweight in Multiple Sclerosis: Disability Progression. Archives of Medical Research, 2017, 48, 113-120.	1.5	26
130	Role of intestinal microbiota in the development of multiple sclerosis. NeurologÃa (English Edition), 2017, 32, 175-184.	0.2	12
131	Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients. Scientific Reports, 2017, 7, 45926.	1.6	37
132	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.	1.1	52
133	Vitamin D and multiple sclerosis: An update. Multiple Sclerosis and Related Disorders, 2017, 14, 35-45.	0.9	183
134	Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort. Journal of Neuroimmunology, 2017, 305, 92-95.	1.1	15
135	Metabolites: deciphering the molecular language between DCs and their environment. Seminars in Immunopathology, 2017, 39, 177-198.	2.8	10

#	Article	IF	Citations
136	Metabolomics: A potential way to know the role of vitamin D on multiple sclerosis. Journal of Pharmaceutical and Biomedical Analysis, 2017, 136, 22-31.	1.4	12
137	Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology, 2017, 13, 25-36.	4.9	730
138	Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 726-731.	1.0	22
139	Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity. Endocrinology and Metabolism Clinics of North America, 2017, 46, 1061-1094.	1.2	143
140	Effects of vitamin D₃in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772729.	0.5	17
141	Biomarkers of Disorders of the Nervous System. , 2017, , 463-610.		2
142	Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772968.	0.5	6
143	Does Multiple Sclerosis Affect the Inpatient Perioperative Outcomes After Total Hip Arthroplasty?. Journal of Arthroplasty, 2017, 32, 3669-3674.	1.5	16
144	Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity. Brain and Behavior, 2017, 7, e00761.	1.0	26
145	Wellness and the Role of Comorbidities in Multiple Sclerosis. Neurotherapeutics, 2017, 14, 999-1017.	2.1	47
146	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA Journal, 2017, 8, 313-325.	3.3	94
147	Role of Vitamin D in Rheumatoid Arthritis. Advances in Experimental Medicine and Biology, 2017, 996, 155-168.	0.8	31
148	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 47-53.	0.9	15
149	Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. Neurotherapeutics, 2017, 14, 135-147.	2.1	13
150	Identification of the miRNAâ€“mRNA regulatory network in multiple sclerosis. Neurological Research, 2017, 39, 142-151.	0.6	42
151	Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress. Journal of the Neurological Sciences, 2017, 381, 213-219.	0.3	31
152	Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism. Frontiers in Psychiatry, 2017, 8, 47.	1.3	59
153	Role of Vitamin D in Multiple Sclerosis Pathogenesis and Therapy. , 2017, , 71-80.		0

#	Article	IF	Citations
154	Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction. Frontiers in Immunology, 2017, 8, 1096.	2.2	100
155	Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?. Journal of Immunology Research, 2017, 2017, 1-14.	0.9	52
156	Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis. PLoS ONE, 2017, 12, e0174726.	1.1	26
157	EBV Infection and Vitamin D in Multiple Sclerosis Patients. , 2017, , 9-20.		1
158	Therapeutic and Prophylactic Potential of Vitamin D for Multiple Sclerosis. , 2017, , .		0
159	Sun exposure over the life course and associations with multiple sclerosis. Neurology, 2018, 90, e1191-e1199.	1.5	44
160	Does vitamin D deficiency predict early conversion of clinically isolated syndrome? A preliminary Egyptian study. International Journal of Neuroscience, 2018, 128, 946-951.	0.8	5
161	Vitamin D and remyelination in multiple sclerosis. NeurologÃa (English Edition), 2018, 33, 177-186.	0.2	12
162	Low vitamin D levels affect outcomes of orthopedic spinal surgery: An observational study in clinical practice. Technology and Health Care, 2018, 26, 305-317.	0.5	1
163	Vitamin D and Autoimmune Diseases. Contemporary Endocrinology, 2018, , 41-55.	0.3	0
164	Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis. Metabolic Brain Disease, 2018, 33, 545-557.	1.4	19
165	Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. Environmental Research, 2018, 163, 43-52.	3.7	50
166	Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts. American Journal of Medicine, 2018, 131, 464-472.	0.6	21
168	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	6.3	1,204
169	Vitamina D y remielinizaciÃ³n en la esclerosis mÃºltiple. NeurologÃa, 2018, 33, 177-186.	0.3	26
170	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	1.4	101
171	Lower 25-Hydroxyvitamin D is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Nutrition, Health and Aging, 2018, 22, 38-43.	1.5	13
172	Exploring the effect of vitamin D₃ supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1280-1287.	1.4	32

#	Article	IF	Citations
173	Diet, Gut Microbiota, and Vitamins D +ÂA in Multiple Sclerosis. Neurotherapeutics, 2018, 15, 75-91.	2.1	117
174	Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal. Journal of Steroid Biochemistry and Molecular Biology, 2018, 180, 137-141.	1.2	16
175	ESPEN guideline clinical nutrition in neurology. Clinical Nutrition, 2018, 37, 354-396.	2.3	301
176	Nutrition et sclÃ©rose en plaquesÂ: le point de la littÃ©rature. Nutrition Clinique Et Metabolisme, 2018, 32, 67-80.	0.2	0
177	Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy, 2018, 7, 59-85.	1.4	245
178	Progressive Forms of Multiple Sclerosis. Neurologic Clinics, 2018, 36, 163-171.	0.8	42
179	Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?. Journal of Neuroimmunology, 2018, 314, 50-57.	1.1	15
180	Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology, 2018, 91, e2256-e2264.	1.5	65
181	Obesity and brain volume loss in multiple sclerosis. Neurology, 2018, 91, 1079-1080.	1.5	1
182	Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3. BioMed Research International, 2018, 2018, 1-9.	0.9	3
183	Multiple sclerosis biomarkers: Helping the diagnosis?. Revue Neurologique, 2018, 174, 364-371.	0.6	13
184	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. Neurological Sciences, 2018, 39, 1467-1470.	0.9	10
185	HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis. Journal of Neuroimmunology, 2018, 321, 117-124.	1.1	8
186	Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact. International Journal of Molecular Sciences, 2018, 19, 2245.	1.8	102
187	Sex-Specific Gene-by-Vitamin D Interactions Regulate Susceptibility to Central Nervous System Autoimmunity. Frontiers in Immunology, 2018, 9, 1622.	2.2	22
188	Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 477.	2.2	52
189	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	1.1	30
190	Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 263.	1.1	24

#	Article	IF	Citations
192	Free Vitamin D. , 2018, , 925-937.		4
193	Pediatric Multiple Sclerosis. , 2018, , 277-294.		0
194	The Way Forward With Vitamin D in Multiple Sclerosis. , 2018, , 175-191.		2
195	The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence. Current Nutrition Reports, 2018, 7, 150-160.	2.1	114
196	Vitamin D and Multiple Sclerosis. , 2018, , 989-1024.		4
197	Gut Microbiota in Brain Development and Disorders of the CNS: Therapeutic Strategies Involving Dietary Modification, Pro- and Prebiotic Intervention, and Fecal Microbiota Transplantation (FMT) Therapy. , 2018, , 517-594.		0
198	Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?. Reviews in the Neurosciences, 2019, 30, 221-232.	1.4	5
199	Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?. Journal of Neuroimmunology, 2019, 329, 1-8.	1.1	11
200	Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a028944.	2.9	103
202	A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients, 2019, 11, 1528.	1.7	65
203	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs, 2019, 33, 1187-1199.	2.7	59
204	Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	70
205	Randomized trial of daily high-dose vitamin D ₃ in patients with RRMS receiving subcutaneous interferon Î²-1a. Neurology, 2019, 93, e1906-e1916.	1.5	88
206	Vitamin D and MRI measures in progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 276-282.	0.9	11
208	Seasonal variations of 25-OH vitamin D serum levels in Multiple Sclerosis patients with relapse using MRI. European Journal of Translational Myology, 2019, 29, 8361.	0.8	3
209	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. PLoS Genetics, 2019, 15, e1008180.	1.5	46
210	Seasonality and Autoimmune Diseases. , 2019, , 229-234.		0
211	Neurological Disorders. , 2019, , 541-548.		0

#	Article	IF	Citations
212	Prevalence and incidence of narcolepsy in a US health care claims database, 2008â€“2010. Sleep, 2019, 42, .	0.6	42
213	Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using wholeâ€exome next generation sequencing. Brain and Behavior, 2019, 9, e01272.	1.0	23
214	Total 25-hydroxy vitamin D level in cerebrospinal fluid correlates with serum total, bioavailable, and free 25-hydroxy vitamin D levels in Korean population. PLoS ONE, 2019, 14, e0213389.	1.1	8
215	The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: A review. Life Sciences, 2019, 224, 33-40.	2.0	22
216	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982840.	0.5	7
217	The role of vitamin D and P2X7R in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 159-169.	1.1	6
218	Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 287-300.	4.9	167
219	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982659.	0.5	11
221	Different vitamin D status in common multiorgan autoimmune disease patients. Journal of Laboratory Medicine, 2019, 43, 243-247.	1.1	0
222	Vitamin D enhances responses to interferon-Î² in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e622.	3.1	26
223	Multiple sclerosis risk factors contribute to onset heterogeneity. Multiple Sclerosis and Related Disorders, 2019, 28, 11-16.	0.9	36
224	Correlation of different cellular assays to analyze T cell-related cytokine profiles in vitamin D3-supplemented patients with multiple sclerosis. Molecular Immunology, 2019, 105, 198-204.	1.0	10
225	The role of glialâ€“neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain. Immunotherapy, 2019, 11, 129-147.	1.0	17
226	Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS). European Journal of Clinical Nutrition, 2020, 74, 167-175.	1.3	19
227	Phloroglucinol derivative compound 21 attenuates cuprizone-induced multiple sclerosis mice through promoting remyelination and inhibiting neuroinflammation. Science China Life Sciences, 2020, 63, 905-914.	2.3	9
228	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	0.9	3
229	Vitamin D increases remyelination by promoting oligodendrocyte lineage differentiation. Brain and Behavior, 2020, 10, e01498.	1.0	40
230	Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients. EPMA Journal, 2020, 11, 65-72.	3.3	18

#	Article	IF	Citations
231	Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. British Journal of Pharmacology, 2020, 177, 4113-4133.	2.7	15
232	Vitamin D supplementation and serum neurofilament light chain in interferonâ€betaâ€1bâ€treated MS patients. Brain and Behavior, 2020, 10, e01772.	1.0	7
233	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652.	3.7	56
234	Narrowband UVB phototherapy reduces TNF production by Bâ€cell subsets stimulated via TLR7 from individuals with early multiple sclerosis. Clinical and Translational Immunology, 2020, 9, e1197.	1.7	11
235	Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 329.	1.1	9
236	The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis and Related Disorders, 2020, 43, 102156.	0.9	10
237	Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases. Multiple Sclerosis and Related Disorders, 2020, 44, 102243.	0.9	9
238	Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients, 2020, 12, 783.	1.7	69
239	Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis. PLoS ONE, 2020, 15, e0230219.	1.1	30
240	Vitamin D and Disease Severity in Multiple Sclerosisâ€"Baseline Data From the Randomized Controlled Trial (EVIDIMS). Frontiers in Neurology, 2020, 11, 129.	1.1	15
241	Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration. Brain, Behavior, and Immunity, 2020, 87, 751-764.	2.0	7
242	Role of diet in regulating the gut microbiota and multiple sclerosis. Clinical Immunology, 2022, 235, 108379.	1.4	19
243	Disorders of myelin. , 2020, , 309-335.		2
244	Vitamin D and Demyelinating Diseases: Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS). Autoimmune Diseases, 2020, 2020, 1-9.	2.7	10
245	SpÃ©cificitÃ©s de la sclÃ©rose en plaques chez les MaghrÃ©binsÂ: rÃ1e des facteurs environnementaux et gÃ©nÃ©tiques. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 421-427.	0.0	0
246	Serum vitamin D level is associated with speed of processing in multiple sclerosis patients. Journal of Steroid Biochemistry and Molecular Biology, 2020, 200, 105628.	1.2	5
247	Daily and seasonal mitochondrial protection: Unraveling common possible mechanisms involving vitamin D and melatonin. Journal of Steroid Biochemistry and Molecular Biology, 2020, 199, 105595.	1.2	49
248	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. Journal of the Neurological Sciences, 2020, 411, 116668.	0.3	26

#	Article	IF	Citations
249	Metabolomics in multiple sclerosis disease course and progression. Multiple Sclerosis Journal, 2020, 26, 591-598.	1.4	36
250	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960.	1.5	45
251	Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. Archives of Dermatological Research, 2021, 313, 1-10.	1.1	14
253	Natural History of Multiple Sclerosis. , 2021, , 89-104.		0
254	Clinical Approach to Autoimmune Myelitis and Myelopathy. , 2021, , 433-445.		0
256	Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. Biomarker Insights, 2021, 16, 117727192110133.	1.0	23
257	Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102732.	0.9	10
258	Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings. Current Drug Discovery Technologies, 2021, 18, 31-46.	0.6	14
259	Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECTÂ® Autoinjector: A Prospective Observational Cohort Study. Frontiers in Neurology, 2021, 12, 643126.	1.1	6
260	Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. Current Opinion in Neurology, 2021, 34, 277-285.	1.8	6
261	Association between the concentration of CYP24A1, 25-OH vit D3 and calcium-phosphate metabolism with an increased risk of multiple sclerosis in Iraqi patients. Journal of Physics: Conference Series, 2021, 1853, 012030.	0.3	0
262	Predicting disability worsening in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 312-321.	1.8	9
263	Vitamin D as disease-modifying therapy for multiple sclerosis?. Expert Review of Clinical Immunology, 2021, 17, 691-693.	1.3	3
264	Association Between Serum Vitamin D Levels and Frequency of Relapses in Patients With Multiple Sclerosis. Cureus, 2021, 13, e14383.	0.2	5
265	RelaciÃ³n entre la vitamina D y la salud sexual y reproductiva masculina. Clinica E Investigacion En Ginecologia Y Obstetricia, 2021, 48, 177-183.	0.1	0
266	Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. Brain, 2021, 144, 1152-1166.	3.7	28
267	A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. International Journal of Molecular Sciences, 2021, 22, 3696.	1.8	12
268	Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies. International Journal of Molecular Sciences, 2021, 22, 4922.	1.8	7

#	Article	IF	Citations
269	Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegenerative Disease Management, 2021, 11, 251-261.	1.2	5
270	Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Frontiers in Neurology, 2021, 12, 693017.	1.1	45
271	Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence. Expert Review of Neurotherapeutics, 2021, 21, 715-725.	1.4	12
273	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102910.	0.9	1
274	The association between vitamin D and uveitis: A comprehensive review. Survey of Ophthalmology, 2021, , .	1.7	4
275	Association of cholesterol 7Î±-hydroxylase (CYP7A1) promoter polymorphism (rs3808607) and cholesterol 24S-hydroxylase (CYP46A1) intron 2 polymorphism (rs754203) with serum lipids, vitamin D levels, and multiple sclerosis risk in the Turkish population. Neurological Sciences, 2022, 43, 2611-2620.	0.9	2
276	Low sun exposure acts synergistically with high Epsteinâ^'Barr nuclear antigen 1 (EBNAâ€1) antibody levels in multiple sclerosis etiology. European Journal of Neurology, 2021, 28, 4146-4152.	1.7	5
277	Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans. Multiple Sclerosis and Related Disorders, 2021, 55, 103185.	0.9	3
278	Assessing environmental epidemiology questions in practice with a causal inference pipeline: An investigation of the air pollutionâ€•multiple sclerosis relapses relationship. Statistics in Medicine, 2021, 40, 1321-1335.	0.8	7
279	Vitamin D and Multiple Sclerosis. Current Clinical Neurology, 2020, , 197-212.	0.1	2
280	Krankheitsbild Multiple Sklerose. , 2016, , 1-12.		3
281	Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials. Journal of Neurology, 2018, 265, 348-355.	1.8	12
282	Treatment Considerations in the Radiologically Isolated Syndrome. Current Treatment Options in Neurology, 2020, 22, 3.	0.7	7
283	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
285	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation, 2020, 130, 3467-3482.	3.9	109
286	Progressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 785-798.	0.4	8
287	Symptom Management and Lifestyle Modifications in Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 815-836.	0.4	13
288	Phases and Phenotypes of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 636-654.	0.4	28

#	Article	IF	Citations
289	Vitamin D and immunity. F1000prime Reports, 2014, 6, 118.	5.9	60
290	Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients. PLoS ONE, 2014, 9, e115488.	1.1	39
291	Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up. PLoS ONE, 2016, 11, e0156122.	1.1	34
292	Vitamin D status in patients with multiple sclerosis: an association with insolation, disease course, and HLA-DRB1 gene polymorphism. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 63-68.	0.2	2
293	Treatment of Multiple Sclerosis â€“ Relationship between Vitamin D and Interferon Î²-1b. European Neurological Review, 2015, 10, 124.	0.5	1
294	Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review. CNS and Neurological Disorders - Drug Targets, 2019, 18, 478-490.	0.8	10
295	A Brief Review of the Effects of Vitamin D on Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 781.	2.2	50
296	MiljÃ¸ets betydning ved multippel sklerose. Tidsskrift for Den Norske Laegeforening, 2015, 135, 856-860.	0.2	10
297	Environmental risk factors for multiple sclerosis: A case-control study in Kerman, Iran. Iranian Journal of Nursing and Midwifery Research, 2018, 23, 431.	0.2	3
298	The Role of Nutritional Lifestyle and Physical Activity in Multiple Sclerosis Pathogenesis and Management: A Narrative Review. Nutrients, 2021, 13, 3774.	1.7	18
299	The Immune Response in Multiple Sclerosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 121-139.	9.6	96
300	Impact of Vitamin D Supplementation on Multiple Sclerosis. Cureus, 2021, 13, e18487.	0.2	6
301	Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 56, 103311.	0.9	2
302	Cloned Microglias with Novel Delivery System in Multiple Sclerosis. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	0
303	Vitamin D Level in Multiple Sclerosis Patients. Could Vitamin D Level Be Routine Investigation for Multiple Sclerosis Patients?. Neuroscience and Medicine, 2014, 05, 201-204.	0.2	2
304	Lipids and Health. , 2014, , 161-302.		0
305	Relationship between Vitamin D Nutritional Status and Human Immunodeficiency Virus Infection. , 2015, , 189-212.		0
306	Vitamin D: Panacea unexplored. Journal of the Ceylon College of Physicians, 2015, 45, 32.	0.0	0

#	Article	IF	Citations
307	Multiple Sklerose: Was kÃ¶nnen wir an ihr verstehen und wie behandeln wir sie?. Der Merkurstab, 2016, 69, 297-313.	0.0	2
308	Shedding Light on Vitamin D and Multiple Sclerosis. , 2016, , 327-345.		0
310	Vitamin D and multiple sclerosis. Klinicka Farmakologie A Farmacie, 2016, 30, 29-31.	0.1	0
311	Other neurological diseases. , 2017, , 95-122.		0
312	Vitamin D and multiple sclerosis. Neurologie Pro Praxi, 2017, 18, 174-178.	0.0	0
313	Vitamin D and the Central Nervous System: Development, Protection, and Disease. Contemporary Endocrinology, 2018, , 227-247.	0.3	2
314	Epigenetic mechanisms in pathogenesis of multiple sclerosis. Open Access Journal of Translational Medicine & Research, 2018, 2, .	0.1	0
315	Influence of vitamin D on clinical-pathogenetic curriculum of multiple sclerosis. Bukovinian Medical Herald, 2018, 22, 30-35.	0.1	0
316	Association Between Sunlight Exposure and Vitamin D Intake and Multiple Sclerosis Disability and Progression. Caspian Journal of Neurological Sciences, 2018, 4, 114-120.	0.1	1
317	Multiple Sklerose: Therapie. Springer Reference Medizin, 2019, , 1-25.	0.0	0
318	Ã‰pidÃ©miologie, environnement et gÃ©nÃ©tique dans la sclÃ©rose en plaques. , 2019, , 31-105.		0
319	Vitamin D and Multiple Sclerosis-Is there a Link?. ARS Medica Tomitana, 2019, 25, 61-63.	0.0	0
321	Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients. , 2019, 10, 200.		2
322	Epidemiology and Genetics. Current Clinical Neurology, 2020, , 71-87.	0.1	1
323	The Effects of Different Kinds of Nutrition and Functional Foods on Multiple Sclerosis. Current Nutrition and Food Science, 2020, 16, 632-637.	0.3	0
324	Assessment of vitamin D-binding protein (DBP) gene polymorphisms and their correlation with multiple sclerosis: a case-control study in a sample of the Syrian population. Egyptian Journal of Medical Human Genetics, 2020, 21, .	0.5	1
325	Multiple Sklerose: Therapie. Springer Reference Medizin, 2020, , 1099-1123.	0.0	0
326	Gut feelings: the microbiota-gut-brain axis on steroids. American Journal of Physiology - Renal Physiology, 2022, 322, G1-G20.	1.6	9

#	Article	IF	Citations
327	A robust method for simultaneous measurement of serum 25(OH)D, 1,25(OH)₂D, and 24,25(OH)₂D by liquid chromatographyâ€tandem mass spectrometry with efficient separation of 3â€epi analogs, 23R,25(OH)₂D₃, and 4Î²,25(OH)₂D₃. Journal of Mass Spectrometry, 2022, 57, e4792.	0.7	3
328	Oxidative Stress and Vitamin D as Predictors in Multiple Sclerosis. Current Health Sciences Journal, 2020, 46, 371-378.	0.2	0
329	Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sciences, 2021, 11, 1521.	1.1	14
330	Vitamin D Supplementation and Mental Health in Multiple Sclerosis Patients: A Systematic Review. Nutrients, 2021, 13, 4207.	1.7	17
331	Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis. PLoS ONE, 2021, 16, e0261097.	1.1	7
332	Nutritional implications for the pathophysiology and treatment of autoimmune disorders. , 2022, , 243-267.		0
333	Microbial agents as triggers of developing multiple sclerosis. Russian Journal of Infection and Immunity, 2022, 11, 1050-1056.	0.2	0
334	Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases. Diagnostics, 2022, 12, 130.	1.3	18
335	In Vivo Assessment of the Ameliorative Impact of Some Medicinal Plant Extracts on Lipopolysaccharide-Induced Multiple Sclerosis in Wistar Rats. Molecules, 2022, 27, 1608.	1.7	4
336	The Relationship of Cobalamin and/or Folate to the Patient-Centred Outcomes in Multiple Sclerosis: A Systematic Review and Meta-analysis. Nutrition and Health, 2022, 28, 527-542.	0.6	1
337	Altered Plasma Metabolic Profiles in Chinese Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 792711.	2.2	5
338	Polymorphisms CYP2R1 rs10766197 and CYP27B1 rs10877012 in Multiple Sclerosis: A Case-Control Study. Journal of Immunology Research, 2021, 2021, 1-11.	0.9	4
339	Impact of carbamazepine on vitamin D levels: A meta-analysis. Epilepsy Research, 2021, 178, 106829.	0.8	7
346	Immune Cell Contributors to the Female Sex Bias in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Current Topics in Behavioral Neurosciences, 2022, , 333-373.	0.8	5
348	Basal metabolic rate and risk of multiple sclerosis: a Mendelian randomization study. Metabolic Brain Disease, 2022, 37, 1855-1861.	1.4	4
349	Ð¯ÐºÑ–ÑŒÑŒ Ð¶Ð¸Ñ‚Ñ•Ñ…Ð²Ð¾Ñ… Ñ–Ð· Ð¼Ð½Ð¾Ð¶Ð¸Ð½Ð½Ð¸Ð¼ ÑÐºÐ»ÐµÑ€Ð¾Ð·Ð¾Ð¼: Ñ‚ÐµÑ€Ð°Ð¿Ñ–Ñ		
351	Therapeutic Advances in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	28
352	Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. Cureus, 2022, , .	0.2	6

#	Article	IF	Citations
353	Association of vitamin D receptor polymorphisms with vitamin D and calcium levels in Turkish multiple sclerosis patients. Neurodegenerative Disease Management, 0, , .	1.2	0
354	Vitamin D Receptor and Its Influence on Multiple Sclerosis Risk and Severity: From Gene Polymorphisms to Protein Expression. Immuno, 2022, 2, 469-481.	0.6	2
355	Exploring the Effect of Genetic, Environmental and Lifestyle Factors on Multiple Sclerosis Susceptibility. , 0, , .		0
356	Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study. Journal of Research in Medical Sciences, 2022, 27, 67.	0.4	1
357	A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 1430.	1.1	6
358	Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide. Frontiers in Immunology, 0, 13, .	2.2	10
359	Vitamin D and bone metabolism in Gravesâ€™ disease: a prospective study. Journal of Endocrinological Investigation, 2023, 46, 425-433.	1.8	5
360	Could the Majority of the Greek and Cypriot Population Be Vitamin D Deficient?. Nutrients, 2022, 14, 3778.	1.7	4
361	Assessment of Serum 25-hydroxyvitamin D Levels at the First Manifestation of Multiple Sclerosis in Children and Adolescents. Trends in Pediatrics, 2022, 3, 62-66.	0.0	0
362	Long-Term Effects of Antiseizure Medications. Seminars in Neurology, 2022, 42, 583-593.	0.5	3
363	Trends in the environmental risks associated with earlier onset in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104250.	0.9	3
364	Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study. Multiple Sclerosis and Related Disorders, 2022, 68, 104395.	0.9	5
365	Vitamin D genetic risk scores in multiple sclerosis. Journal of Neurology, 2023, 270, 1030-1035.	1.8	0
366	Role of the intestinal microbiota in the pathogenesis of multiple sclerosis. Part 1. Clinical and experimental evidence for the involvement of the gut microbiota in the development of multiple sclerosis. Meditsinskii Akademicheskii Zhurnal, 2022, 2, 9-36.	0.2	1
367	Lifestyle Measures in Multiple Sclerosis. US Neurology, 2022, 18, 122.	0.2	3
368	Vitamin D deficiency in relation with the systemic and central inflammation during multiple sclerosis. Journal of Medical Biochemistry, 2023, 42, 364-375.	0.7	1
369	Vitamin D in Neurological Diseases. International Journal of Molecular Sciences, 2023, 24, 87.	1.8	13
370	Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity. Clinical Epigenetics, 2022, 14, .	1.8	10

#	Article	IF	Citations
371	Radiological Benefits of Vitamin D Status and Supplementation in Patients with MSâ€"A Two-Year Prospective Observational Cohort Study. Nutrients, 2023, 15, 1465.	1.7	3
373	Biological sciences underpinning biomechanics. , 2023, , 391-493.		0
374	Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 93, 263-273.	1.2	2
375	Clinical and Imaging Outcomes after Vitamin D Supplementation in Patients with Multiple Sclerosis: A Systematic Review. Nutrients, 2023, 15, 1945.	1.7	4
376	Perception of Quality of Life and Fatigue in Multiple Sclerosis Patients Treated with High-Dose Vitamin D. Clinical and Translational Neuroscience, 2023, 7, 12.	0.4	1
377	Association between vitamin D deficiency and multiple sclerosis- MRI significance: A scoping review. Heliyon, 2023, 9, e15754.	1.4	2
380	Dietary management of multiple sclerosis. , 2023, , 527-543.		0
381	Considerations on vitamin D supplementation in multiple sclerosis. , 2023, , 359-377.		0
392	Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested caseâ€"control study in an English population-based cohort. Journal of Neurology, 2024, 271, 241-253.	1.8	2
394	Vitamin D mechanisms of protection in multiple sclerosis. , 2024, , 1129-1166.		0
395	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0
397	Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence. Journal of Neurology, 2024, 271, 1536-1570.	1.8	1
401	Epidemiology, epigenetics, and etiological factors in multiple sclerosis. , 2024, , 67-96.		0